Australia's industry body to review direction:
This article was originally published in Clinica
Executive Summary
The Medical Industry Association of Australia (MIAA) is to develop a new strategic plan as part of an attempt to decide how it can best help its members meet and help shape the changing industrial environment. "Our industry is experiencing substantial change - and we need to develop an agreed view of just what [it] will look like five years out," said MIAA CEO Brian Vale. Mergers, takeovers, the decline in manufacturing and the rise of e-commerce are all contributing to the emerging environment, according to Mr Vale.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.